Kelyniam Global Inc
Kelyniam Global, Inc., a medical device manufacturing company, engages in the production of custom prosthetics cranial implants utilizing computer aided design, and computer aided manufacturing of advanced medical grade polymers in the United States. The company is also involved in the development, manufacture, and distribution of custom cranial implant for patients requiring the reconstruction o… Read more
Kelyniam Global Inc (KLYG) - Net Assets
Latest net assets as of March 2025: $721.07K USD
Based on the latest financial reports, Kelyniam Global Inc (KLYG) has net assets worth $721.07K USD as of March 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($1.73 Million) and total liabilities ($1.01 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $721.07K |
| % of Total Assets | 41.72% |
| Annual Growth Rate | N/A |
| 5-Year Change | 85.26% |
| 10-Year Change | 34.23% |
| Growth Volatility | 33.68 |
Kelyniam Global Inc - Net Assets Trend (2006–2024)
This chart illustrates how Kelyniam Global Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Kelyniam Global Inc (2006–2024)
The table below shows the annual net assets of Kelyniam Global Inc from 2006 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $884.41K | +42.70% |
| 2023-12-31 | $619.76K | -18.59% |
| 2022-12-31 | $761.26K | +9.84% |
| 2021-12-31 | $693.07K | +45.18% |
| 2020-12-31 | $477.39K | +74.46% |
| 2019-12-31 | $273.64K | -54.75% |
| 2018-12-31 | $604.67K | -0.92% |
| 2017-12-31 | $610.30K | -11.00% |
| 2016-12-31 | $685.75K | +4.08% |
| 2015-12-31 | $658.88K | -11.16% |
| 2014-12-31 | $741.63K | +9.59% |
| 2013-12-31 | $676.71K | +1037.41% |
| 2007-12-31 | $-72.19K | -185.98% |
| 2006-12-31 | $-25.24K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Kelyniam Global Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 308485700.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $49.72K | 5.62% |
| Other Components | $4.03 Million | 456.09% |
| Total Equity | $884.41K | 100.00% |
Kelyniam Global Inc Competitors by Market Cap
The table below lists competitors of Kelyniam Global Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Kool2play SA
WAR:K2P
|
$1.79K |
|
PlantFuel Life Inc
PINK:PLFLF
|
$1.80K |
|
B92
LSE:B90
|
$1.80K |
|
Xsovt Brands Inc
PINK:XSVT
|
$1.80K |
|
Sardar Chemical Industries Ltd
KAR:SARC
|
$1.79K |
|
Enzymatica AB
F:EN9
|
$1.79K |
|
Kafr El Zayat Pesticides
EGX:KZPC
|
$1.79K |
|
Egyptian Starch & Glucose
EGX:ESGI
|
$1.79K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Kelyniam Global Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 619,759 to 884,413, a change of 264,654 (42.7%).
- Net loss of 920,206 reduced equity.
- Other factors increased equity by 1,184,860.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-920.21K | -104.05% |
| Other Changes | $1.18 Million | +133.97% |
| Total Change | $- | 42.70% |
Book Value vs Market Value Analysis
This analysis compares Kelyniam Global Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 10.12x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2006-12-31 | $0.00 | $0.18 | x |
| 2007-12-31 | $0.00 | $0.18 | x |
| 2013-12-31 | $0.03 | $0.18 | x |
| 2014-12-31 | $0.04 | $0.18 | x |
| 2015-12-31 | $0.03 | $0.18 | x |
| 2016-12-31 | $0.03 | $0.18 | x |
| 2017-12-31 | $0.03 | $0.18 | x |
| 2018-12-31 | $0.02 | $0.18 | x |
| 2019-12-31 | $0.01 | $0.18 | x |
| 2020-12-31 | $0.02 | $0.18 | x |
| 2021-12-31 | $0.03 | $0.18 | x |
| 2022-12-31 | $0.03 | $0.18 | x |
| 2023-12-31 | $0.02 | $0.18 | x |
| 2024-12-31 | $0.02 | $0.18 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Kelyniam Global Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -104.05%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -27.65%
- • Asset Turnover: 1.88x
- • Equity Multiplier: 2.00x
- Recent ROE (-104.05%) is below the historical average (-23.74%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2006 | 0.00% | -164.89% | 0.83x | 0.00x | $-111.66K |
| 2007 | 0.00% | -392.34% | 0.69x | 0.00x | $-175.48K |
| 2012 | -110.95% | -20.17% | 0.00x | 0.00x | $-265.27K |
| 2013 | 2.21% | 0.80% | 1.39x | 1.98x | $-52.73K |
| 2014 | -0.64% | -0.27% | 1.33x | 1.77x | $-78.94K |
| 2015 | -6.07% | -2.63% | 1.26x | 1.84x | $-105.85K |
| 2016 | -1.97% | -0.89% | 1.17x | 1.90x | $-82.09K |
| 2017 | -11.89% | -3.92% | 1.58x | 1.91x | $-133.57K |
| 2018 | -2.53% | -0.72% | 1.69x | 2.07x | $-75.77K |
| 2019 | -130.81% | -16.40% | 1.43x | 5.57x | $-385.32K |
| 2020 | 29.55% | 5.62% | 1.91x | 2.75x | $93.34K |
| 2021 | 29.11% | 7.57% | 1.86x | 2.06x | $132.43K |
| 2022 | -12.82% | -3.23% | 1.77x | 2.24x | $-173.69K |
| 2023 | -35.25% | -8.18% | 1.64x | 2.63x | $-280.45K |
| 2024 | -104.05% | -27.65% | 1.88x | 2.00x | $-1.01 Million |
Industry Comparison
This section compares Kelyniam Global Inc's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $694,749,556
- Average return on equity (ROE) among peers: -25.46%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Kelyniam Global Inc (KLYG) | $721.07K | 0.00% | 1.40x | $1.79K |
| Advanced Biomedical Technologies Inc (ABMT) | $-4.46 Million | 0.00% | 0.00x | $14.18K |
| Abbott Laboratories (ABT) | $4.82 Billion | 39.04% | 1.31x | $191.37 Billion |
| Acarix AB (publ) (ACIXF) | $1.93 Million | -127.02% | 0.21x | $26.42 Million |
| Adagio Medical Holdings, Inc Common Stock (ADGM) | $-72.62 Million | 0.00% | 0.00x | $4.05 Million |
| Adm Tronics Unltd (ADMT) | $-12.69K | 0.00% | 0.00x | $3.17 Million |
| Aethlon Medical Inc (AEMD) | $-3.07 Million | 0.00% | 0.00x | $2.79 Million |
| Acutus Medical Inc (AFIB) | $126.58 Million | -80.56% | 0.52x | $732.88K |
| Adapthealth Corp (AHCO) | $2.07 Billion | 7.56% | 1.54x | $914.25 Million |
| Allied Healthcare Products Inc. (AHPIQ) | $8.88 Million | -33.95% | 1.22x | $726.24 |
| 20/20 Biolabs, Inc. Common Stock (AIDX) | $3.39 Million | -59.65% | 0.38x | $9.18 Million |